Anebulo Pharmaceuticals Completes $21M IPO

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction, completed its $21 million initial public offering (IPO) of 3,000,000 shares of common stock at a public offering price of $7.00 per share. The common stock began trading on The Nasdaq Capital Market on May 7, 2021 under the ticker symbol ANEB. The Benchmark Company, LLC acted as the sole book running manager for the offering. Faegre Drinker represented Benchmark in the transaction.